Tenaya Therapeutics (TNYA) EBITDA Margin (2026)
Tenaya Therapeutics (TNYA) posted quarterly EBITDA Margin of 8917.78% for Q1 2026.
Tenaya Therapeutics (TNYA) EBITDA Margin (2026) Analysis & Trends
Tenaya Therapeutics' EBITDA Margin history runs 1 years deep, the most recent figure standing at 8917.78% for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 19.75% |
| 10 | Tenaya Therapeutics | 155.44 Mn | 155.44 Mn | - | -3,971.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,971.89% |
| Mar 31, 2026 | -8,917.78% |